This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva, others fail to get immediate appeal in US antitrust case over Sensipar

( February 16, 2023, 22:31 GMT | Official Statement) -- MLex Summary: Teva Pharmaceuticals, Watson Laboratories, Actavis Pharma failed to persuade a US federal judge to immediately certify an order for appeal. District Judge Leonard P. Stark entered an order in March finding that a patent settlement over Sensipar could constitute a “reverse payment.” District Judge Colm F. Connolly said he could not certify an interlocutory appeal on an order he didn't enter after Stark was elevated to an appeals court.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections